The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes

New England Journal of Medicine

Volumn 345, Issue 14, 2001, Pages 1014-1021

  De Lemos, James A ^a,b,f   Morrow, David A ^a,c   Bentley, Jane H ^d   Omland, Torbjorn ^e   Sabatine, Marc S ^a,c   McCabe, Carolyn H ^a,c   Hall, Christian ^e   Cannon, Christopher P ^a,c   Braunwald, Eugene ^a,c  

^a Thrombolysis in Myocardial Infarction Study Group   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Nottingham Clinical Research Group   (United Kingdom)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DISEASE MARKER; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; SUDDEN DEATH; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ATRIAL NATRIURETIC FACTOR; C-REACTIVE PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC;

EID: 0035807597     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011053     Document Type: Article

References (30)

1. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: Influence of angiotensin II and diastolic fiber length
2. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
3. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
4. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease
5. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
6. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size
7. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction
8. Profile of plasma N-terminal proBNP following acute myocardial infarction: Correlation with left ventricular systolic dysfunction
9. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction
10. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction
11. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
12. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
13. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction
14. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
15. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
16. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB trial
17. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting
18. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty
19. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction
20. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction
21. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris
22. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty
23. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty
24. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina
25. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
26. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study
27. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
28. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI 11B substudy
29. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
30. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels